Welcome to our dedicated page for TNF Pharmaceuticals SEC filings (Ticker: TNFA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TNFA SEC filings page on Stock Titan provides access to the regulatory history of TNF Pharmaceuticals, Inc., the company that later became Q/C Technologies, Inc. and now trades on Nasdaq under the ticker QCLS. These filings document key corporate events, financing transactions and the formal name and ticker symbol change that marked the company’s shift from a clinical stage biopharmaceutical focus toward quantum-class photonic computing and blockchain infrastructure.
Among the notable documents is an 8-K filed on September 26, 2025, which reports the filing of a Certificate of Amendment to change the corporate name from TNF Pharmaceuticals, Inc. to Q/C Technologies, Inc. and confirms that the company’s common stock ceased trading under TNFA and began trading under QCLS on the Nasdaq Stock Market. Other 8-K and 8-K/A filings describe a Securities Purchase Agreement for a private placement of Series H convertible preferred stock and warrants, the creation of Series I convertible preferred stock in connection with the acquisition of LPU Holdings LLC, and amendments to existing Series F and Series F-1 preferred stock designations.
Filings also include a Form 12b-25 (NT 10-Q), in which the company explains that it was unable to file its Quarterly Report on Form 10-Q for the six months ended June 30, 2025, within the prescribed time period without unreasonable effort or expense and anticipated filing within the allowed extension period. Together, these documents give insight into the company’s capital structure, preferred stock terms, acquisition agreements, licensing arrangements with LightSolver Ltd., and steps taken to manage its SEC reporting obligations.
On Stock Titan, users can review these TNFA filings alongside AI-powered summaries designed to clarify complex sections of 8-Ks, preferred stock designations and related agreements. Real-time updates from EDGAR ensure that new or amended filings tied to the historical TNFA entity and its successor Q/C Technologies appear promptly. Investors can also use the platform to track ownership and capital structure changes associated with preferred stock and warrants, and to connect the formal regulatory record with the company’s strategic pivot into quantum-class computing and blockchain infrastructure.
TNF Pharmaceuticals (TNFA) reported significant operating losses and financing activity for the six months ended June 30, 2025. The company recorded a net loss of $19,365,689 (six months) and $2,920,938 (three months) with research and development expenses of $2,418,985 (six months) and $873,472 (three months). Preferred stock dividends materially reduced results, totaling $1,789,865 (six months) and $976,369 (three months).
The filing discloses heavy financing through multiple preferred series and warrant issuances, conversions and anti-dilution adjustments (Series F, F-1, G and D), and large share issuances during the period. The company reports negative operating cash flows and states substantial doubt about its ability to continue as a going concern without additional capital. The company also received a Nasdaq notice regarding a minimum bid price deficiency and has a compliance period to regain the $1.00 minimum bid requirement.
TNF Pharmaceuticals, Inc. filed a notice that it will not submit its Quarterly Report on Form 10-Q for the six months ended June 30, 2025 on time. The company states it needs additional time to complete and finalize the financial statements required for this report. It expects to file the Form 10-Q on or before the fifth calendar day after the original due date, relying on the automatic extension provided under SEC Rule 12b-25.